Codagenix
Codagenix is a biotechnology company that develops live-attenuated viral vaccines using its proprietary SAVE (Synthetic Attenuated Virus Engineering) platform, which relies on synthetic biology and computer-aided redesign of the target virus entire genome to yield vaccine strains. The SAVE platform recodes viral genomes by strategically altering codon usage without changing the encoded proteins, creating attenuated…
Funding snapshot
About
Codagenix is a biotechnology company that develops live-attenuated viral vaccines using its proprietary SAVE (Synthetic Attenuated Virus Engineering) platform, which relies on synthetic biology and computer-aided redesign of the target virus entire genome to yield vaccine strains. The SAVE platform recodes viral genomes by strategically altering codon usage without changing the encoded proteins, creating attenuated viruses that replicate sufficiently to trigger immune responses but are too weak to cause disease. Codagenix pipeline includes vaccine candidates targeting seasonal influenza, dengue virus, respiratory syncytial virus (RSV), and other infectious diseases, with candidates in preclinical and clinical development stages. The company approach enables rapid vaccine design and manufacturing scalability compared to traditional vaccine development methods. Founded in 2011 and headquartered in Stony Brook, New York, Codagenix has raised $47.1 million through Series B funding from investors including Adjuvant Capital, Serum Institute of India, Euclidean Capital, and the NIH.
Business model
Oncology > Drugs > Diversified,
Infectious Diseases > Drugs > Viral > Diversified,
Genomics > Applied Genomics > Synthetic Biology,
Life Sciences Platforms and Tools > Research Services > Diversified
Institutional investors
Backed by funds in our directory
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.